drugset / Trial / NCT02858180

Hepatitis C Virus(HCV) Heart and Lung Study

NCT02858180

Phase 4 Completed 15 enrolled Duke University Gilead Sciences · collab
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is a multicenter study in Hepatitis C Virus (HCV) infected adult patients who also have advanced cardiac disease or advanced lung disease.

Timeline

Start
2016-12
Primary completion
2019-04-11
Completion
2019-07-04

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Ledipasvir Small molecule 90 mg Oral
Subject Sofosbuvir Small molecule 400 mg Oral